bioAffinity Technologies, Inc.
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | $1.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | $1.40M | $-0.81 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 13, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $1.50M | $-4.74 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $1.30M | $-0.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | $1.90M | $-0.16 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $2.40M | $-0.16 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 9, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Mar 31, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total revenue | 2025 | $6.00M to $8.00M | New |
| sales of CyPath lung tests | 2025 | $1.00M to $2.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements bioAffinity Technologies filed with the SEC
Technologies to Present New Perspectives on CyPath ® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Other events · EX-99.1 to Form 8-K
Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and
Other events · EX-99.1 to Form 8-K
Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Other events · EX-99.1 to Form 8-K
Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
Other events · EX-99.1 to Form 8-K
Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with
Other events · EX-99.1 to Form 8-K
Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
Other events · EX-99.1 to Form 8-K
Technologies Announces Grant of Hong Kong Patent for Company’s CyPath ® Lung Noninvasive Lung Cancer Diagnostic
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Technologies to Participate in the H.C. Wainwright 28 th Annual Global Investment Conference
Other events · EX-99.1 to Form 8-K
Technologies Advances CyPath ® Lung for Surveillance of Lung Cancer Survivors
Other events · EX-99.1 to Form 8-K
Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
Other events · EX-99.1 to Form 8-K
Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Results of operations · EX-99.1 to Form 8-K
Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer
Other events · EX-99.1 to Form 8-K
Technologies and Pictor ® , Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
Other events · EX-99.1 to Form 8-K
Technologies’ Quarterly CyPath ® Lung Sales Double to New Record as Commercial Momentum Continues
Other events · EX-99.1 to Form 8-K
what’s happening at bioAffinity Technologies…
Other events · EX-99.1 to Form 8-K
Technologies Announces Pricing of $3.2 Million Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Technologies Announces Closing of $3.2 Million Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches
Other events · EX-99.1 to Form 8-K
Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society
Other events · EX-99.1 to Form 8-K
Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath ®
Other events · EX-99.1 to Form 8-K
Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
Other events · EX-99.1 to Form 8-K
Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath ® Lung
Results of operations · EX-99.1 to Form 8-K
Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging
Other events · EX-99.1 to Form 8-K
Technologies’ CyPath ® Lung to be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection”
Other events · EX-99.1 to Form 8-K
Technologies’ CyPath ® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
Other events · EX-99.1 to Form 8-K
Case Study: bioAffinity Technologies’ CyPath ® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive
Other events · EX-99.1 to Form 8-K
Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
Results of operations · EX-99.1 to Form 8-K
of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath ® Lung Cancer Diagnostic
Other events · EX-99.1 to Form 8-K
Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath ®
Other events · EX-99.1 to Form 8-K
Case Study Highlights Ability of bioAffinity Technologies’ CyPath ® Lung to Reduce Diagnostic Burden for Patients
Other events · EX-99.1 to Form 8-K